ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

plozasiran

Also written as “Plozasiran Injection”, “ARO-APOC3” and “Plozasiran”.

Its studies are mostly in Hypertriglyceridemia · Dyslipidemias · Hyperlipoproteinemia Type I, led by 2 companies.

Drug pagePlozasiran: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 11, 202112 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticalsits history only102 open or runningphase 3since Oct 11, 2021Dec 19, 2018Jul 2028phase 3 · NCT06822790
Visirna Therapeutics HK20 open or runningphase 3since May 31, 2023Feb 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Visirna Therapeutics HK only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2023First study: phase 1 study in Healthy Adult VolunteersFirst studyNCT05757596 · 24 enrolled · China
  2. May 31, 2023Phase 3 study in Familial hyperchylomicronemia syndromeNCT05902598 · 37 enrolled · China
  3. Feb 29, 2024Named plozasiranINNProposed as its International Nonproprietary Name in WHO's List 130

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Visirna Therapeutics HK leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05902598Familial hyperchylomicronemia syndrome · China3CompletedNov 26, 202437
NCT05757596Healthy Adult Volunteers · China1CompletedSep 25, 202324

How it is read

Names in the registry

  • “Plozasiran Injection”, 4 entries
  • “ARO-APOC3”, 4 entries
  • “Plozasiran”, 3 entries
  • “VSA001 injection”, 1 entry

Codes read as this program: VSA001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.